Trans-retinoic acid and related differentiation agents.
Interest in retinoids as therapeutic agents has developed as a result of the observations of remission induction with all-trans retinoic acid (tRA) in patients with acute promyelocytic leukemia (APL), and of high objective response rates noted with the combination of cis-retinoic acid (cRA) with interferon-alpha in squamous cell carcinomas of skin and cervix. The therapeutic experience with RA in APL is discussed in this article from the perspectives of new information concerning retinoid biology, observations related to the development of the retinoid syndrome, complex pharmacology of this agent, and possible explanations for development of retinoid resistance. The current National Cancer Institute-supported drug development strategy for RA used alone or in combination with other differentiating agents, and the potential therapeutic uses in cancer for other retinoids are also discussed.
Parkinson
D R
DR
Division of Cancer Treatment, National Cancer Institute, Bethesda, MD 20892.
Smith
M A
MA
Cheson
B D
BD
Stevenson
H C
HC
Friedman
M A
MA
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D012176:Retinoids / Q000494:pharmacology / Q000627:therapeutic use*; D014212:Tretinoin / Q000627:therapeutic use
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D012176:Retinoids; D014212:Tretinoin